RemeGen Co., Ltd. (Yantai) was co-founded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, and Dr. Jianmin Fang a Canadian-American scientist. RemeGen is headquartered in Yantai, Shandong Province, China, with R&D centers and offices in China and the United States.
The World’s First Innovative Dual-Target Biological Medication to Treat Systemic Lupus Erythematosus
The First Independently Developed Novel ADC Drug in China
【2024.05.07】 Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
【2024.04.26】 [Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
The Annual European Association of Urology Congress 2026 (EAU Congress 2026), one of the world’s premier urological events, was held in London, the United Kingdom, from March 13 to 16, 2026 (UTC+0). At the congress, results of multiple researches
Address: No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.
Telephone:（+86）535-3573511
News
On February 27 local time, at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) held in San Francisco, USA, the latest efficacy and safety data from the extended follow-up of the phase II clinical study (RC48-C017) o
On January 15 at 9:00 a.m. local time, Dr. Jianmin Fang, CEO of RemeGen, took the stage at the 44th J.P. Morgan Healthcare Conference in San Francisco—a premier global event for pharmaceutical innovation and investment trends. In his keynote address
On January 12, Rongchang Biopharmaceutical (Yantai) Co., Ltd. (688331.SH/09995.HK, hereinafter referred to as "Rongchang Bio") announced the signing of an exclusive licensing agreement with AbbVie Group Holdings (hereinafter referred to as "
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally adv
YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-targ
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceuti
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase I
YANTAI, China, Aug. 8, 2025 /PRNewswire/ -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed
Chicago, US, June 2, 2025 (UTC-8)—In a rapid oral abstract session of the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the result of a Phase 2 clinical trial conducted in China to evaluate the efficacy and safety of
官方微信
官方微信